Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +53

Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More

📈 Citi opened a 90-day upside catalyst watch on Agilent Technologies following a pending $950 million acquisition of Biocare Medical.

💰 Citi named Agilent its top life science tools pick, assigning it a Buy rating with a $185 price target above the current trading level.

🩺 Natera was designated as Citi's top diagnostics pick after returning to profitability with Q4 2025 EPS of $0.36 versus an estimated -$0.4998.

🔬 Charles River Laboratories received its top contract research organization pick designation as the firm works toward returning to organic growth in H2 2026.

⚠️ Citi cut Icon PLC's price target from $200 to $120 and maintained a Neutral rating due to an internal accounting investigation regarding potential revenue overstatement.

📉 Icon's stock dropped 41% year-to-date with quarterly earnings growth falling 98.7% year-over-year following the disclosure of accounting issues in February 2026.

💧 Agilent shares fell 15% year-to-date to $115.43 but improved Q1 FY2026 revenue by 7% year-over-year to $1.80 billion.

🏆 The Broad analyst community remains constructive on Agilent with 15 Buy or Strong Buy ratings versus 6 Hold ratings and a consensus target of $163.29.

📉 Icon PLC's stock trades below book value at a price-to-book ratio of 0.9 following sharp declines driven by the accounting investigation.

📈 Natera has been the sector's standout performer, rising 50% over the past 12 months despite a recent 13.16% pullback to $198.95.

⚠️ Icon's Q4 and full-year 2025 results will be delayed until on or before April 30, 2026, pending accounting clarity.

🤝 Agilent's acquisition of Biocare Medical adds over 300 specialized antibodies and tissue diagnostic capabilities to its pathology portfolio.

🕒 Citi's catalyst watch mechanism signals that Agilent's valuation multiple is expected to rebound within roughly 90 days upon the deal close.

📊 The sector reset reflects Wall Street's preference for names with clear near-term catalysts or improving fundamentals over those navigating structural uncertainty.

🚀 All four companies analyzed carry elevated beta, meaning they tend to amplify broader market moves in both directions during volatile periods.

Bullish Signals
  • Citi opened a 90-day upside catalyst watch on Agilent Technologies and named it its top tools pick, signaling strong confidence in the company's recovery trajectory.
  • Agilent's acquisition of Biocare Medical for $950 million adds over 300 specialized antibodies to its pathology portfolio, strengthening its position in a roughly $10 billion market.
  • The pending deal is expected to close by Q4 FY2026, after which Citi anticipates Agilent's valuation multiple should rebound significantly.
  • Agilent raised its full-year revenue guidance to $7.3 billion to $7.5 billion, demonstrating management's confidence in sustained top-line growth.
  • The CrossLab services segment delivered $758 million in revenue with a strong 31.6% operating margin, highlighting profitable high-margin operations.
  • Broad analyst sentiment remains constructive on Agilent, with 15 Buy or Strong Buy ratings versus only 6 Hold ratings and a consensus price target of $163.29.
  • Natera returned to profitability with Q4 2025 EPS of $0.36 against an estimated loss of -$0.4998, dramatically exceeding expectations and earning its top diagnostics pick designation.
  • Charles River Laboratories is guiding for a return to organic growth in the second half of 2026 as it works through a cyclical trough.
  • Citi maintains a Buy rating on Agilent with an $185 price target, well above current trading levels, providing meaningful upside potential from today's price of $115.43.
Risk Factors
  • Icon PLC faces significant downside risk after Citi analyst Patrick Donnelly cut its price target from $200 to $120, signaling caution on the stock.
  • The company's accounting investigation into potential revenue overstatement across fiscal years 2023 through 2025 introduces substantial earnings uncertainty that complicates modeling the investment case.
  • Icon PLC shares have dropped 41% year to date and 41.65% over the past year, trading at $106.62 — a significant discount from its 52-week high of $211.00.
  • Fundamentals have softened alongside the investigation risks, with quarterly earnings growth falling 98.7% year over year on a trailing basis.
  • The stock trades below book value at a price-to-book ratio of 0.9, indicating potential undervaluation concerns or market skepticism about its asset quality.
  • Agilent Technologies shares have pulled back sharply from recent highs, falling 15% year to date to $115.43 as of March 10.
  • The stock sits well below its 52-week high of $159.98 and its 50-day moving average of $132.49, reflecting continued downward pressure despite improving fundamentals.
  • All four names in the sector carry elevated beta, with Icon and Agilent at 1.3 and Natera at a volatile 1.70, amplifying broader market downturns in both directions.
  • Charles River Laboratories sits below its 200-day moving average of $172.30 after declining 16.1% year to date to $167.37, suggesting continued cyclical weakness.
Full Analysis
Citi adjusted its ratings and price targets across the life science sector on Wednesday, initiating a 90-day upside catalyst watch for Agilent Technologies while cutting its price target on Icon PLC amid a turbulent earnings season. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River Laboratories its top contract research organization pick. These moves reflect a broader strategic reset as Wall Street positions portfolios heading into the second quarter, balancing selective optimism on recovery candidates with caution on entities facing significant accounting or operational uncertainty. For Agilent, the investment thesis centers on the potential for multiple re-rating following the expected removal of an acquisition overhang regarding its pending purchase of Biocare Medical. Announced March 9, 2026, the $950 million all-cash deal is valued to add more than 300 specialized antibodies and tissue diagnostic capabilities to Agilent's pathology portfolio, strengthening its position in a roughly $10 billion market. Citi holds a Buy rating with a $185 target, noting that once the deal closes by the fourth quarter of fiscal 2026, the stock's valuation should rebound. Currently trading at $115.43, Agilent has fallen 15% year to date but has shown improving fundamentals with Q1 FY2026 revenue up 7% year over year at $1.80 billion and a raised full-year revenue guidance range of $7.3 billion to $7.5 billion. In contrast, Citi analyst Patrick Donnelly cut Icon PLC's price target from $200 to $120, maintaining a Neutral rating after Icon disclosed an internal accounting investigation involving potential revenue overstatement across fiscal years 2023 through 2025. Icon subsequently delayed its Q4 and full-year 2025 results, which are now expected on or before April 30, 2026, introducing significant earnings uncertainty until restated financials clarify the scope of any adjustments. The firm sees limited upside to near-term outlooks for Icon until accounting clarity arrives, though it acknowledges room for improvement if biopharma activity continues to strengthen. Meanwhile, Natera was named the top diagnostics pick after reporting Q4 2025 EPS of $0.36 against an estimate of -$0.4998, marking a return to profitability following years of widening losses. Charles River Laboratories received the top CRO designation as the company works through a cyclical trough with management guiding for organic growth in the second half of 2026.